| Literature DB >> 30991736 |
Elvyra Stanevičiūtė1, Inga Urtė Builytė2, Martynas Ridziauskas3, Justinas Besusparis4,5, Agnė Kirkliauskienė6, Vaidotas Zabulis7, Linas Davainis8, Gabrielė Valiūnaitė9, Vytautas Triponis10, Vytautas Sirvydis11.
Abstract
Background and objectives: Treatment of a prosthetic vascular graft infection (PVGI) remains a challenging problem in vascular surgery. The aim of this study was to design a novel rat model for treatment of peripheral vascular prosthesis infection caused by Staphylococcus aureus (S. aureus) and to determine the efficacy of different antiseptic solutions in suppressing or eradicating infection from the wound and the graft material itself. Materials and methods: A piece of Dacron vascular prosthesis was surgically implanted at the dorsum of 48 Wistar rats and the wounds were infected with 5 McFarland standard inoculum of S. aureus. Suppurating wounds were daily irrigated with different antiseptic solutions: octenidine dihydrochloride, povidone-iodine, chlorhexidine digluconate, and sterile saline. The antimicrobial action of antiseptics was defined according to their capability to eradicate bacteria from the graft surroundings and bacteriological examination of the graft itself. Extended studies on wound microbiology, cytology, and histopathology were performed with an additional group of 10 rats, treated with the most effective antiseptic-octenidine dihydrochloride.Entities:
Keywords: S. aureus; antiseptic; rat model; vascular graft infection
Mesh:
Substances:
Year: 2019 PMID: 30991736 PMCID: PMC6524009 DOI: 10.3390/medicina55040106
Source DB: PubMed Journal: Medicina (Kaunas) ISSN: 1010-660X Impact factor: 2.430
Changes in rat’s body weight associated with antiseptic used for treatment of PVGI *.
| Antiseptic Solution | Octenidine Dihydrochloride | Povidon-Iodine | Chlorhexidine Digluconate | Control Group (Sterile Saline) |
|---|---|---|---|---|
| Mean body weight at day 1, g | 318.5 ± 40.1 | 323.1 ± 58.2 | 312.5 ± 48.6 | 316.2 ± 52.0 |
| Mean body weight at day 10, g | 299.3 ± 44.1 | 306.2 ± 60.6 | 276.4 ± 54.3 | 313.9 ± 50.0 |
| Mean change of body weight, g | −19.25 ± 59.6 | −16.9 ± 83.9 | −36.1 ± 72.9 | −2.3 ± 72.1 |
| Effect size, Cohen’s d | −0.32 | −0.2 | −0.49 | -0.03 |
| Change in body weight, % | −5.9 | −5.6 | −11.5 | −0.1 |
| 0.048 | 0.004 | 0.043 | 0.566 |
* PVGI-prosthetic vascular graft infection
Figure 1An arrow in the image points to a hardened swelling at the incision site with a purulent fistula on day six—before the beginning of treatment.
Figure 2Changes in S. aureus colony counts in wound washouts along the time of treatment. Four-day treatment course resulted in significant drop in S. aureus colony counts for octenidine group (p = 0.0005, n = 12), povidone-iodine group (p = 0.002, n = 10), and chlorhexidine group (p = 0.004, n = 10). Insignificant change was detected in control group (p = 0.765, n = 11).
Figure 3Macroscopic findings of the wound for rat treated with octenidine dihydrochloride (day 13): (A) a crust at the incision site; (B) a cutaneous fistula at the incision site; and (C) excised cutaneous fistula with a crust for microbiological and histopathological evaluation.
Figure 4The results of extended PVGI treatment with octenidine dihydrochloride. Seven-day treatment course resulted in significant drop in S. aureus colony counts in wound washouts (p = 0.002, n = 10).
Histopathological evaluation of subcutaneous and muscle tissue for rats treated with octenidine dihydrochloride.
| Rat Number | Area of Necrosis in Subcutaneous and Muscle Tissue, % | Type of Inflammation in Subcutaneous and Muscle Tissue |
|---|---|---|
| 1 | 1.90 | Minor PMN * |
| 2 | 0 | Xantogranulomatous |
| 3 | 11.58 | Xantogranulomatous |
| 4 | 0 | Xantogranulomatous |
| 5 | 1.17 | None |
| 6 | 20.77 | Minor PMN |
| 7 | 0 | Xantogranulomatous |
| 8 | 0 | None |
| 9 | 22.48 | Mild PMN |
| 10 | 10.04 | Minor PMN |
* PMN-polymorphonuclearic